公开(公告)号：US20230125803A1

公开(公告)日：2023-04-27

申请号：US17894412

申请日：2022-08-24

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D491/052 ,  C07D471/04 ,  C07D491/044 ,  C07D491/048

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220227746A1

公开(公告)日：2022-07-21

申请号：US17574718

申请日：2022-01-13

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Adam Szymaniak ,  Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D413/14 ,  A61P31/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10851115B2

公开(公告)日：2020-12-01

申请号：US16023363

申请日：2018-06-29

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： In Jong Kim ,  Joseph Panarese ,  Thomas P. Blaisdell ,  Jianming Yu ,  Brian C. Shook ,  Yat Sun Or

IPC: C07D519/00 ,  A61P31/16

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20200223867A1

公开(公告)日：2020-07-16

申请号：US16739312

申请日：2020-01-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph Panarese ,  Yat Sun Or

IPC: C07D513/04 ,  A61K31/56 ,  A61K31/58 ,  A61K31/5513 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US12006326B2

公开(公告)日：2024-06-11

申请号：US17894412

申请日：2022-08-24

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D491/052 ,  C07D471/04 ,  C07D491/044 ,  C07D491/048

CPC classification number: C07D491/052 ,  C07D471/04 ,  C07D491/044 ,  C07D491/048

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11952389B2

公开(公告)日：2024-04-09

申请号：US17735258

申请日：2022-05-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D235/24 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  A61P31/14 ,  A61P31/16 ,  C07D243/16 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08 ,  C07D513/04

CPC classification number: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08 ,  A61K31/5513 ,  A61K2300/00 ,  A61K31/58 ,  A61K2300/00 ,  A61K31/56 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230365525A1

公开(公告)日：2023-11-16

申请号：US18139405

申请日：2023-04-26

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jianming Yu ,  Xiben Li ,  Robert Leon ,  Adam Szymaniak ,  In Jong Kim ,  Yat Sun Or

IPC: C07D401/12 ,  C07D417/12 ,  C07D401/14 ,  C07D413/14 ,  A61K45/06 ,  A61P31/14 ,  C07D471/04 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14

CPC classification number: C07D401/12 ,  C07D417/12 ,  C07D401/14 ,  C07D413/14 ,  A61K45/06 ,  A61P31/14 ,  C07D471/04 ,  C07D417/14 ,  C07D409/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230115580A1

公开(公告)日：2023-04-13

申请号：US17720079

申请日：2022-04-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Jianming Yu ,  Kevin McGrath ,  Xiben Li ,  Tyler J. Mann ,  Robert Leon ,  In Jong Kim ,  Yat Sun Or ,  Long Nguyen

IPC: C07D491/048 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11534439B2

公开(公告)日：2022-12-27

申请号：US17368238

申请日：2021-07-06

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: A61K31/498 ,  C07D491/107 ,  C07D519/00 ,  A61K45/06 ,  A61K31/4985 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11505558B1

公开(公告)日：2022-11-22

申请号：US17220300

申请日：2021-04-01

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Adam Szymaniak ,  Kevin McGrath ,  Jianming Yu ,  Tyler Mann ,  Long Nguyen ,  Kaicheng Zhu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D471/04 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.